PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Comparative effectiveness in multiple sclerosis: A methodological comparison

Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola

2023-03-01

BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trial..

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin, C Malpas, J Lechner-Scott, M Slee, P McCombe, S Vucic, E Butler, S Hodgkinson, M Barnett, O Skibina, A van der Walt, K Buzzard, C Shaw, A Kermode, B Taylor, N Shuey, R Macdonell, H Butzkueven, T Kalincik

2022-12-01

BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); how..

Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Steve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, Edward De Brouwer, Lotte Geys, Tina Parciak, Anne Helme, Nick Rijke, Jan A Hillert, Yves Moreau, Gilles Edan, Sifat Sharmin, Tim Spelman, Robert McBurney, Hollie Schmidt, Arnfin B Bergmann, Stefan Braune, Alexander Stahmann, Rod M Middleton, Amber Salter

2022-11-01

BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies..

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-beta

Steve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, Liesbet M Peeters, Lotte Geys, Tina Parciak, Anne Helme, Jan Hillert, Yves Moreau, Gilles Edan, Tim Spelman, Sifat Sharmin, Robert McBurney, Hollie Schmidt, Arnfin Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Bruce Bebo

2022-07-30

BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS...

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study

Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Vahid Shaygannejad, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Catherine Larochelle, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison

2022-06-14

BACKGROUND AND OBJECTIVES: The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants..

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M Lefort, S Sharmin, JB Andersen, S Vukusic, R Casey, M Debouverie, G Edan, J Ciron, A Ruet, J De Seze, E Maillart, H Zephir, P Labauge, G Defer, C Lebrun-Frenay, T Moreau, E Berger, P Clavelou, J Pelletier, B Stankoff

2022-05-30

BACKGROUND: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several obs..

Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi -National Registry

Sifat Sharmin, Charles Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, Marc Girard

2022-05-03

BACKGROUND: Early recognition of markers of faster disability worsening in paediatric-onset multiple sclerosis (MS) is a key requi..

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

Tomas Kalincik, Ilya Kister, Tamar E Bacon, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala-Havrdova, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani

2022-04-03

BACKGROUND: The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estim..

Multiple Sclerosis Relapses Following Cessation of Fingolimod

Charles B Malpas, Izanne Roos, Sifat Sharmin, Katherine Buzzard, Olga Skibina, Helmut Butzkueven, Ludwig Kappos, Francesco Patti, Raed Alroughani, Dana Horakova, Eva Kubala Havrdova, Guillermo Izquierdo, Sara Eichau, Suzanne Hodgkinson, Pierre Grammond, Jeannette Lechner-Scott, Tomas Kalincik

2022-03-18

BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. R..

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan A Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clement Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavanai, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin B Bergmann

2021-11-09

BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-1..

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Eva Kubala Havrdova, Raed Alroughani, Guillermo Izquierdo, Serkan Ozakbas, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, Francois Grand'Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz

2021-09-18

INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting mult..

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach

2021-08-31

OBJECTIVE: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactiv..

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Johanna B Andersen, Sifat Sharmin, Mathilde Lefort, Nils Koch-Henriksen, Finn Sellebjerg, Per Soelberg Sorensen, Claudia C Hilt Christensen, Peter Rasmussen, Michael B Jensen, Jette L Frederiksen, Stephan Bramow, Henrik K Mathiesen, Karen Schreiber, Dana Horakova, Eva K Havrdova, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Francesco Patti

2021-06-08

BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsi..

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad

2021-02-02

OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS),..

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis

Nathaniel Lizak, Charles B Malpas, Sifat Sharmin, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Sara Eichau, Alessandra Lugaresi, Pierre Duquette, Marc Girard, Alexandre Prat, Catherine Larochelle, Maria Trojano, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raymond Hupperts, Roberto Bergamaschi, Cavit Boz

2020-11-01

IMPORTANCE: It is unclear whether relapses and disease-modifying therapies are associated with the rate of disability accumulation..

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi

2020-09-01

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies re..

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Amy Kunchok, Jeannette Lechner-Scott, Franco Granella, Maria Trojano, Raed Alroughani, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Marco Onofrj, Serkan Ozakbas, Guillermo Izquierdo, Pierre Grammond, Jose Luis Sanchez-Menoyo, Bart Van Wijmeersch, Cavit Boz, Eugenio Pucci, Pamela McCombe, Francois Grand'Maison, Daniele Spitaleri, Steve Vucic

2020-07-08

BACKGROUND: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging ..

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Le Minh, Charles Malpas, Sifat Sharmin, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Catherine Larochelle, Raed Alroughani, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Pierre Grammond, Francois Grand' Maison

2020-06-15

BACKGROUND: Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values re..

Early clinical markers of aggressive multiple sclerosis

Charles B Malpas, Ali Manouchehrinia, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Francois Grand'Maison, Serkan Ozakbas, Vincent Van Pesch

2020-05-01

Patients with the ‘aggressive’ form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Di..

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Tim Spelman, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alessandra Lugaresi, Raymond Hupperts, Patrizia Sola, Diana Ferraro, Jan Lycke, Francois Grand'Maison, Alexandre Prat

2020-04-01

BACKGROUND: High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line dise..

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG neuromyelitis optica spectrum disorder

Amy Kunchok, Charles Malpas, Petra Nytrova, Eva Kubala Havrdova, Raed Alroughani, Murat Terzi, Bassem Yamout, Jyh Yung Hor, Rana Karabudak, Cavit Boz, Serkan Ozakbas, Javier Olascoaga, Magdolna Simo, Franco Granella, Francesco Patti, Pamela McCombe, Tunde Csepany, Bhim Singhal, Roberto Bergamaschi, Yara Fragoso

2020-02-01

BACKGROUND: Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous sys..

Risk of secondary progressive multiple sclerosis: A longitudinal study

Adam Fambiatos, Vilija Jokubaitis, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Raymond Hupperts, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci

2019-08-09

BACKGROUND: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly con..

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Tomas Kalincik, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Marco Onofrj, Alessandra Lugaresi, Serkan Ozakbas, Ludwig Kappos, Jens Kuhle, Murat Terzi, Jeannette Lechner-Scott, Cavit Boz, Francois Grand'Maison, Julie Prevost, Patrizia Sola, Diana Ferraro

2019-04-01

OBJECTIVE: Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of t..

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, Alessandra Lugaresi, Roberto Bergamaschi, Pierre Grammond, Raed Alroughani, Raymond Hupperts, Pamela McCombe, Vincent Van Pesch, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi

2019-01-15

IMPORTANCE: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a pha..

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Jordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, Raymond Hupperts, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Cristina Ramo-Tello, Maria Trojan, Mark Slee, Vahid Shaygannejad, Cavit Boz, Jeanette Lechner-Scott, Vincent Van Pesch, Eugenio Pucci

2018-11-01

IMPORTANCE: The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) ..

Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Jeannette Lechner-Scott, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Claudio Solaro, Francois Grand'Maison, Raymond Hupperts, Julie Prevost, Patrizia Sola, Diana Ferraro, Murat Terzi, Ernest Butler

2018-10-01

OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolim..

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Johannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, Guillermo Izquierdo, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Maria Trojano, Pierre Duquette, Marc Girard, Alexandre Prat, Francois Grand'Maison, Pierre Grammond, Eugenio Pucci, Cavit Boz, Patrizia Sola, Diana Ferraro, Daniele Spitaleri, Jeanette Lechner-Scott, Murat Terzi

2017-09-05

OBJECTIVE: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive mul..

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani

2017-09-01

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response var..

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Bernd Merkel, Helmut Butzkueven, Anthony L Traboulsee, Eva Havrdova, Tomas Kalincik

2017-06-01

BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with im..

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, Francois Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolanos, Marcela Fiol

2016-04-01

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatmen..

Defining reliable disability outcomes in multiple sclerosis

Tomas Kalincik, Gary Cutter, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Raymond Hupperts, Celia Oreja-Guevara, Cavit Boz, Eugenio Pucci, Roberto Bergamaschi, Jeannette Lechner-Scott

2015-11-01

Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Th..

Defining secondary progressive multiple sclerosis

J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, D Horakova, M Trojano, G Izquierdo, M Girard, P Duquette, A Prat, A Lugaresi, F Grand'Maison, P Grammond, R Hupperts, R Alroughani, P Sola, C Boz, M Terzi, E Pucci

2015-09-01

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja-Guevara, Roberto Bergamaschi, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernandez-Bolanos, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul

2015-08-01

BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been in..

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Anna He, Tim Spelman, Vilija Jokubaitis, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Marc Girard, Eugenio Pucci, Gerardo Iuliano, Raed Alroughani, Celia Oreja-Guevara, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Patrizia Sola, Daniele Spitaleri, Franco Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson

2015-03-01

OBJECTIVE: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..